The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Douglas L Boggs; Toral Surti; Aarti Gupta; Swapnil Gupta; Mark Niciu; Brian Pittman; Ashley M Schnakenberg Martin; Halle Thurnauer; Andrew Davies; Deepak C D'Souza; Mohini Ranganathan

doi:10.1007/s00213-018-4885-9

Back

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Journal article

Peer reviewed

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, …

Psychopharmacology (Berlin, Germany), Vol.235(7), pp.1923-1932

07/2018

DOI: 10.1007/s00213-018-4885-9

PMID: 29619533

View Online

Abstract

Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial. This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly. There was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug × time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group. At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects. https://clinicaltrials.gov/ct2/show/NCT00588731.

Cannabidiol - administration & dosage

Follow-Up Studies

Humans

Middle Aged

Male

Mental Status and Dementia Tests

Schizophrenic Psychology

Psychiatric Status Rating Scales

Outpatients - psychology

Schizophrenia - diagnosis

Cognition - physiology

Cognitive Dysfunction - psychology

Adult

Female

Cognitive Dysfunction - diagnosis

Cognitive Dysfunction - drug therapy

Affect - drug effects

Double-Blind Method

Administration, Oral

Affect - physiology

Treatment Outcome

Cognition - drug effects

Antipsychotic Agents - administration & dosage

Schizophrenia - drug therapy

Chronic Disease

Details

Title: Subtitle: The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Creators: Douglas L Boggs - Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Toral Surti - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Aarti Gupta - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Swapnil Gupta - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Mark Niciu - Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD, USA
Brian Pittman - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Ashley M Schnakenberg Martin - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Halle Thurnauer - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Andrew Davies - GW Pharmaceuticals, Cambridge, UK
Deepak C D'Souza - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA
Mohini Ranganathan - Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA. Mohini.Ranganathan@yale.edu
Resource Type: Journal article
Publication Details: Psychopharmacology (Berlin, Germany), Vol.235(7), pp.1923-1932
DOI: 10.1007/s00213-018-4885-9
PMID: 29619533
NLM abbreviation: Psychopharmacology (Berl)
ISSN: 0033-3158
eISSN: 1432-2072
Publisher: Germany
Grant note: 07TGS-1082 / Stanely Medical Research Institute
Language: English
Date published: 07/2018
Academic Unit: Psychiatry; Iowa Neuroscience Institute
Record Identifier: 9984003956602771

Metrics

34 Record Views

177 Times Cited - Web of Science

See more details